26 October 2025 - Eisai and Biogen announced today that Health Canada has issued a notice of compliance with conditions for humanised anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 non-carriers or heterozygotes and who have confirmed amyloid pathology. 

Leqembi is the first treatment for early AD that targets an underlying cause of the disease, to be authorised in Canada.

Read Biogen press release